ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. ANGLE plc’s lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer for personalised cancer care. ANGLE plc has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA approval process is underway for the clinical market in the US.